India, April 26 -- As we draw to the end of World Parkinson's Awareness Month, it is timely to reflect on effective advances made in treatments. There are many new therapies that might show promise for the future, including stem cell therapy and gene therapy. Unfortunately, prasinezumab, the monoclonal antibody that targets aggregated a-synuclein did not fulfil is expected early promise. However there is an emerging treatment for Parkinson's disease involving light therapy that targets the microbiome-gut-brain-axis which shows great promise. We are pioneering this therapy in Australia and it has produced a global first in maintaining improvements in slowing disease progression, and in some cases reversing those symptoms. We have prioritis...